Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity

14 Sept 2020

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac electrophysiology and arrhythmias
Share to Neuroscience and Neural Engineering
Share to Receptor Mechanisms and Signaling

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32931730
DOI: 10.1016/j.stem.2020.08.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce ToxicityPMID 32931730Read ↗

Use of hiPSC-derived cardiomyocytes to study LQTS-variant specific proarrhythmic effects of drugs.Semantic proximity Read ↗

Human Engineered Heart Tissue Models for Disease Modeling and Drug DiscoverySemantic proximity Read ↗

Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.Semantic proximity Read ↗

Industrialization of three-dimensional hiPSC-cardiac microtissues for high-throughput cardiac safety and drug discovery screeningSemantic proximity Read ↗

Stars in the Night Sky: iPSC-Cardiomyocytes Return the Patient Context to Drug ScreeningSemantic proximity Read ↗

Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity ScreeningSemantic proximity Read ↗

Management of Engraftment Arrhythmias Associated with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes TransplantationSemantic proximity Read ↗

In vitro to in vivo extrapolation from 3D hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrhythmia risk assessmentSemantic proximity Read ↗

Integrated hiPSC-based liver and heart microphysiological systems predict unsafe drug-drug interactionSemantic proximity Read ↗

Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden deathSemantic proximity Read ↗

Evaluation of the Efficacy and Safety of a Clinical Grade Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Patch: A Pre-Clinical StudySemantic proximity Read ↗

Computational Model for Simulating Drug-Induced Arrhythmia Sensitivity of Human iPSC-derived CardiomyocytesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.